HAYWARD, Calif. — Impax Labs on Monday announced the its board of directors appointed G. Frederick Wilson as the company's president and CEO, effective April 29. Wilkinson previously served as president of Actavis Global Research and Development at Actavis. He succeeds Larry Hsu, Ph.D.
"A long-time industry leader, Fred's extensive experience in managing generic, brand, R&D, and regulatory and compliance activities, together with his track record in driving change, delivering growth, advancing pipeline products and driving innovation, make him the perfect candidate for this role," said Robert L. Burr, Chairman of Impax Labs. "I have every confidence that Fred's vision and passion will translate into remarkable success for Impax. The Board would like to thank Dr. Hsu for his incredible dedication and commitment over the last 18 years and for positioning the company for its next phase of growth."
Wilkinson joined Watson Pharmaceuticals — which is now Actavis — as EVP global brands in September 2009. Prior to his time at Watson, he served as president and COO of Duramed Pharmaceuticals. Before starting at Duramed, he numerous senior management positions at Columbia Labs and Sandoz. Wilkinson received an M.B.A from Capital University and a B.S. in pharmacy from Ohio Northern University
Dr. Hsu, who announced his retirement in 2013, will continue to serve on the Impax Board.